Adjuvant Nivolumab or Ipilimumab plus Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab-MedSci.cn

Adjuvant Nivolumab or Ipilimumab plus Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab

Khan, TM; Teke, ME; Karakousis, GC; Miura, JT; Brody, RM; Hernandez, JM; Mitchell, TC

Hernandez, JM (通讯作者)，Natl Canc Inst, Natl Inst Hlth, Surg Oncol Program, Bethesda, MD 20814 USA.;Mitchell, TC (通讯作者)，Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Adjuvant Nivolumab or Ipilimumab plus Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab

科室

工具

服务